LIWANLI Innovation Co., Ltd. (3054.TW) Stock

About LIWANLI Innovation Co., Ltd.

LIWANLI Innovation Co., Ltd. operates within the biomedical science sector, concentrating on the development and distribution of nutrition and healthcare solutions. The company's diverse product portfolio, which notably features the Vigoway line and various powdered formulations, is designed to serve a wide range of consumers, including men, women, seniors, and children. Its extensive offerings encompass products such as probiotic enzymes, active nutrients, resveratrol red grape extract, and a variety of soft gels (including those with algae DHA, shea butter with type II collagen, and algae astaxanthin Q10). Other specialized items include cordyceps militaris powder, tooth guard tablets, bovine and goat's milk bites, bilberry tablets, and DHA and vitamin D3 drops, among others. The firm was formerly known as Carry Technology International Co., Ltd. before officially adopting its current name, LIWANLI Innovation Co., Ltd., in 2015. Established in 1980, the company's headquarters are located in New Taipei City, Taiwan.

LIWANLI Innovation Co., Ltd. is led by CEO Li-Ching Chen, employs 360 people, headquartered in Taipei, TW, publicly traded since 2002.

over the past 52 weeks the stock has ranged between $22.00 and $96.00, and currently trades 42.7% below its 52-week high.

Official website: www.liwanli.com.tw

LIWANLI Innovation Co., Ltd. (3054.TW) — frequently asked questions